Interactions between T lymphocytes and endothelial cells in allograft rejection

Current Opinion in Immunology

Volumn 10, Issue 5, 1998, Pages 525-531

  Briscoe, David M ^a   Alexander, Stephen I ^b   Lichtman, Andrew H ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CHEMOKINE; GLYCOPROTEIN GP 39;

APOPTOSIS; CELL INTERACTION; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GRAFT REJECTION; HELPER CELL; LYMPHOCYTE SUBPOPULATION; REVIEW; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

EID: 0031726955     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80218-5     Document Type: Article

References (88)

1. Briscoe DM, Ganz P, Alexander SI, Melder RJ, Jain RK, Cotran RS, Lichtman AH. The problem of chronic rejection: influence of leukocyte-endothelial interactions. Kidney Int. 58:1997;S22-S27.
2. Pober JS, Orosz CG, Rose ML, Savage COS. Can graft endothelial cells initiate a host anti-graft immune response? Transplantation. 61:1996;343-349.
3. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
4. Bradley LM, Watson SR. Lymphocyte migration into tissue: the paradigm derived from CD4 subsets. Curr Opin Immunol. 8:1996;312-320.
5. Briscoe DM, Yeung AC, Schoen FJ, Alfred EN, Stavrakis G, Ganz P, Cotran RS, Pober JS. Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts. Transplantation. 59:1995;204-211.
6. + cells do not. The binding of T cells to selectins was assessed under flow conditions and the in vitro acquisition of functional selectin ligands was shown to be induced by stimulation of the T cell antigen receptor plus costimulatory signals. Both naïve and activated T cells were shown to expres PSGL-1 (P-selectin glycoprotein ligand 1) protein, implying that post-translational modifications required for function were restricted to the activated T cells.
7. Lichtman AH, Abbas AK. T-cell subsets: recruiting the right kind of help. Curr Biol. 7:1997;R242-R244.
8. Borges E, Tietz W, Steegmaier M, Moll T, Hallmann R, Hamann A, Vestweber D. P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper 2 cells binds to P-selectin and supports migration into inflammed skin. of special interest J Exp Med. 185:1997;573-578 This paper demonstrates that post-translational modifications, required for functional PSGL-1 expression, occur in mouse Th1 but not Th2 cells. Together with [9], it establishes that the Th1 and Th2 subsets have different abilities to home to peripheral inflammatory site, based in part differences on selectin-ligand expression.
9. Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U, Renz H, Hallmann R, Scheffold A, Rdbruch A, et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. of special interest Nature. 385:1997;81-83 This is the first study to show that Th1 and Th2 cells have different capabilities to home to sites of immune-mediated inflammation. The paper shows that mouse Th1 cells bind soluble P-selectin while Th2 cells do not. In addition, adoptive transfer experiments in mice indicate that Th1 cells, but not Th2 cells, accumulate at sites of delayed-type hypersensitivity in the skin and in joints with adjuvant-induced arthritis. The Th1 recruitment to these sites could be blocked by a combination of antibodies to E-selectin and to P-selectin.
10. Van Wely CA, Blanchard AD, Britten CJ. Differential expression of alpha3 fucosyltransferases in Th2 cells correlates with their ability to bind P-selectin. of special interest Biochem Biophys Res Commun. 247:1998;307-311 The restricted expression of functional selectin ligands in Th1 cells but not Th2 cells (see [8] and [9]) is partially explained by this brief study of fucosyltransferase expression; mRNA expression and functional enzyme activities of fucosyltransferase IV and VII were significantly higher in mouse Th1 cells compared to Th2 cells. Both enzymes have been shown in the past to be involved in the production of selectin ligands in different cells types.
11. Wasowska B, Wieder KJ, Hancock WW, Zheng XX, Berse B, Binder J, Strom TB, Kupiec-Weglinski JW. Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin. J Immunol. 156:1996;395-404.
12. Nickerson P, Steiger J, Zheng XX, Steele AW, Steurer W, Roy-Chaudhury P, Strom TB. Manipulation of cytokine networks in transplantation: false hope or realistic opportunity for tolerance? Transplantation. 63:1997;489-494.
13. Strom TB, Roy-Chaudhury P, Manfro R, Zheng XX, Nickerson PW, Wood K, Bushell A. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol. 8:1996;688-693.
14. Lakkis FG, Konieczny BT, Saleem S, Baddoura FK, Linsley PS, Alexander DZ, Lowry RP, Pearson TC, Larsen CP. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. of outstanding interest J Immunol. 158:1997;2443-2448 For many years it has been suggested that long-term allograft survival, or tolerance, results from selective activation of the Th2-cell-mediated immune pathway. Blockade of CD28-mediated costimulation induces tolerance and increased levels of IL-4. In this study the authors used knockout mice to demonstrate that blockade of CD28-mediated costimulation induces tolerance that is independent of IL-4 production. These results suggest that IL-4 production and the subsequent generation of a Th2-type immune response are not obligatory for long-term acceptance of vascularized allografts.
15. Saleem S, Konieczny BT, Lowry RP, Baddoura FK, Lakkis FG. Acute rejection of vascularized heart allografts in the absence of IFNgamma. Transplantation. 62:1996;1908-1911.
16. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol. 15:1997;675-705.
17. Kondo T, Novick AC, Toma H, Fairchild RL. Induction of chemokine gene expression during allogeneic skin graft rejection. Transplantation. 61:1996;1750-1757.
18. Kondo T, Watarai Y, Novick AC, Toma H, Fairchild RL. T cell-dependent acceleration of chemoattractant cytokine gene expression during secondary rejection of allogeneic skin grafts. of special interest Transplantation. 63:1997;732-742 This study extended the observations in [17] and demonstrated that there were higher levels of MIP (macrophage inflammatory protein)-1α, MIP-1β, RANTES (regulated by activation, normal-T-cell expressed and secreted) and IP-10 (IFN-γ-induced protein 10) expression in presensitized mice and during second-set skin allograft rejection than in unprimed mice; furthermore, when T cells were deleted from animals, there was no chemokine or cytokine expression in the skin allografts. Collectively, both of these studies [17 and 18] suggest a role for chemokine genes during rejection.
19. Fairchild RL, VanBuskirk AM, Kondo T, Wakely ME, Orosz CG. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. of special interest Transplantation. 63:1997;1807-1812 This study demonstrated that IP-10 (IF-γ-induced protein 10), MCP (monocyte chemotactic protein)-1 and KC were prominent by day three after transplantation in cardiac allograft rejection. RANTES (regulated by activation, normal-T-cell expressed and secreted) was expressed later, by day eight. There was little chemokine expression in isografts. This is one of the first studies to demonstrate a potential role for chemokines in acute cardiac allograft rejection.
20. Nadeau KC, Azuma H, Tilney NL. Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1. Proc Natl Acad Sci USA. 92:1995;8729-8733.
21. Nagano H, Nadeau KC, Takada M, Kusaka M, Tilney NL. Sequential cellular and molecular kinetics in acutely rejecting renal allografts in rats. Transplantation. 63:1997;1101-1108.
22. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM. CCR5 is characteristic of Th1 lymphocytes. of outstanding interest Nature. 391:1998;344-345 This study, of chemokine receptors on lymphocytes, demonstrated that CCR5 is expressed and is functional on Th1 lymphocytes but not on Th2 lymphocytes. Th2 cells but not Th1 cells were noted to express moderate levels of CCR3. In addition, lymphocytes infiltrating human rheumatoid synovium, know to be a Th1-like inflammatory site, were shown to express high levels of CCR5 and borderline levels of CCR3 by immunohistochemistry. This study, together with [23] and [24], provides evidence that selective recruitment patterns of Th1 and Th2 lymphocytes is regulated in part by differential expression of chemokoine receptors.
23. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 2 lymphocytes. of special interest J Exp Med. 187:1998;875-883 This study was a follow-up to an earlier paper [24] and demonstrated selective expression of chemokine receptors by subsets of helper T (Th) cells. Naive T cells expressed only CXCR4, whereas the majority of memory T cells expressed CXCR3 and a small proportion expressed CCR3 and CCR5. When differentiated T cells were analyzed, CXCR3 was found to be expressed at high levels on Th0 and Th1 lymphocytes but at low levels on Th2 lymphocytes. In contrast, CCR3 and CCR4 were found on Th2 lymphocytes. Expression of chemokine receptors in T cell subsets was confirmed by functional responses.
24. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. of outstanding interest Science. 277:1997;2005-2007 This study demonstrated the relatively selective expression of CCR3 on Th2 but not Th1 cells; furthermore, in T cell differentiation assays, expression of CCR3 was found to correlate with acquisition of Th2 responses.
25. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. Chemokines and the arrest of lymphocytes rolling under flow conditions. of special interest Science. 279:1998;381-384 In this paper, experiments are reported showing that stromal-cell-derived factor 1α, macrophage inflammatory protein 3β and 6-C-kine triggered robust, integrin-dependent adhesive interactions under flow conditions, within two minutes of activation.
26. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammtory cytokines. J Biol Chem. 273:1998;4282-4287.
27. Craigen JL, Yong KL, Jordan NJ, MacCormac LP, Westwick J, Akbar AN, Grundy JE. Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology. 92:1997;138-145.
28. Billstrom MA, Johnson GL, Avdi NJ, Worthen GS. Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection. J Virol. 72:1998;5535-5544.
29. Baggiolini M. Chemokines and leukocyte traffic. Nature. 392:1998;565-568.
30. Hughes CC, Savage CO, Pober JS. Endothelial cells augment T cell interleukin 2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J Exp Med. 171:1990;1453-1467.
31. Savage CO, Hughes CC, Pepinsky RB, Wallner BP, Freedman AS, Pober JS, Hughes CC, Savage CO, Pober JS. Endothelial cell lymphocyte function-associated antigen-3 and an unidentified ligand act in concert to provide costimulation to human peripheral blood CD4+ T cells. Cell Immunol. 137:1991;150-163.
32. Ma W, Pober JS. Human endothelial cells effectively costimulate cytokine production by but not differentiation of naive CD4+ T cells. of outstanding interest J Immunol. 1998; This study, along with [33], demonstrates that endothelial cells can costimulate effector cytokine production, including interferon-γ and interleukin-4; nonetheless, the results indicate that endothelial costimulation is not sufficient to drive naïve T cells toward Th1 or Th2 phenotypes.
33. + T cell production of IFN-γ and that this costimulatory effect is enhanced by IL-12.
34. Sultan P, Schechner JS, McNiff JM, Hochman PS, Hughes CC, Lorber MI, Askenase PW, Pober JS. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol. 15:1997;759-762.
35. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol. 14:1996;591-617.
36. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 16:1998;111-135.
37. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA, Aruffo A. Expression of functional CD40 by vascular endothelial cells. J Exp Med. 182:1995;33-40.
38. Karmann K, Hughes CCW, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 92:1995;4342-4346.
39. Yellin MJ, Brett J, Baum D, Matsushima A, Szabolcs M, Steern D, Chess L. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med. 182:1995;1857-1864.
40. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA. 89:1992;6550-6554.
41. Reul RM, Fang JC, Denton MD, Geehan C, Long C, Mitchell RN, Ganz P, Briscoe DM. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. of outstanding interest Transplantation. 64:1997;1765-1774 This study was the first to establish the regulated expression of CD40 in human allografts. CD40 was predominantly expressed on microvessels in rejecting allografts and was also evident on a subset of infiltrates. In addition, this study confirmed the findings in [42] that CD40L is expressed by endothelial cells in vitro and in vivo.
42. Mach F, Schonbeck U, Sukhova GK, Bouchier T, Bonnefoy J, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: implications of CD40-CD40 ligand signaling in atherosclerosis. of outstanding interest Proc NAtl Acad Sci USA. 94:1997;1931-1936 In this study, CD40L expression by saphenous vein endothelial cells was demonstrated by RT-PCR, flow cytometry and western blotting. In addition, endothelial cell CD40L was found to be functional in that it induced the expression of the costimulatory molecule B7-1 on a B-cell line.
43. Ochs HD, Hollenbaugh D, Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin Immunol. 6:1994;337-341.
44. Grewal IS, Flavell RA. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today. 17:1996;410-414.
45. Van Essen D, Kikutani H, Gray D. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature. 378:1995;620-623.
46. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 94:1997;8789-8794.
47. Roy M, Aruffo A, Ledbeter JA, Linsley PS, Kehry M, Noelle R. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol. 25:1995;596-603.
48. Blotta MH, Marshall JD, DeKruyff RH, Umetsu DT. Crosslinking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that up-regulates IL-4 synthesis. J Immunol. 156:1996;3133-3140.
49. McLellan A, Sorg R, Williams L, Hart D. Human dendritic cells activate T lymphocytes via a CD40: CD40 Ligand dependent pathway. Eur J Immunol. 26:1996;1204-1210.
50. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, Korngold R, Noelle R, Vallera DA. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 158:1997;29-39.
51. Durie FH, Aruffo A, Ledbetter JA, Crassi KM, Green WR, Fast LD, Noelle RJ. Antibody to the ligand of CD40, gp39, blocks the occurence of acute and chronic forms of graft vs host disease. J Clin Invest. 94:1994;1333-1338.
52. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381:1996;434-438.
53. Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A, Hendrix R, Pearson TC. CD40-gp39 interactions play a critical role during allograft rejection. Transplantation. 61:1996;4-9.
54. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol. 9:1997;641-647.
55. Denton MD, Reul RM, Dharnidharka VR, Fang FC, Ganz P, Briscoe DM. Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. Pediat Transplantation. 2:1998;6-15.
56. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. of outstanding interest Nature. 391:1998;591-594 This paper describes a potentially important way in which endothelial cell CD40 may be triggered in the setting of vascular injury and thrombosis. The study demonstrates that CD40L is rapidly expressed on activated platelets and interacts with endothelial cell CD40 to induce adhesion-molecule expression and chemokine secretion.
57. Peng X, Kasran A, Warmerdam PA, de Boer M, Ceuppens JL. Accessory signaling by CD40 for cell T activation: induction of and Th2 cytokines and synergy with interleukin-12 for intereron-gamma production. Eur J Immunol. 26:1996;1621-1627.
58. Peng X, Remacle JE, Kasran A, Huylebroeck D, Ceuppens JL. IL-12 up-regulates CD40 ligand (CD154) expression on human T cells. J Immunol. 160:1998;1166-1172.
59. McDyer JF, Goletz TJ, Thomas E, June CH, Seder RA. CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12-and/or CD28-dependent manner. J Immunol. 160:1998;1701-1707.
60. Karmann K, Hughes CCW, Fanslow WC, Pober JS. Endothelial cells augment the expression of CD40 ligand on newly activated human CD4+ T cells through a CD2/LFA-3 signaling pathway. Eur J Immunol. 26:1996;610-617.
61. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280:1998;243-248.
62. Sugihara A, Saiki S, Tsuji M, Tsujimura T, Nakata Y, Kubota A, Kotake T, Terada N. Expression of Fas and Fas ligand in the testes and testicular germ cell tumors: an immunohistochemical study. Anticancer Res. 17:1997;3861-3865.
63. Sanberg PR, Saporta S, Borlongan CV, Othberg AI, Allen RC, Cameron DF. The testis-derived cultured Sertoli cell as a natural Fas-L secreting cell for immunosuppressive cellular therapy. Cell Transplant. 6:1997;191-193.
64. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic imunosuppression. Diabetes. 46:1997;317-322.
65. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
66. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
67. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 3:1997;738-743.
68. Kang SM, Lin Z, Ascher NL, Stock PG. Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection. Transplant Proc. 30:1998;538.
69. Sata M, Walsh K. TN Falpha regulation of Fas ligand expression on the vascular endothelium moduletes leukocyte extravasation. of outstanding interest Nat Med. 4:1998;415-420 This paper present both in vitro and in vivo data indicating that functional FasL is expressed on endothelial cells; furthermore, endothelial cell FasL appears to prevent leukocyte infiltration by stimulating apoptosis of adherent leukocytes. Interestingly, TNF-α downregulates endothelial cell FasL, an effect which would work in synergy with other proinflammatory effect of TNF-α such as upregulation of endothelial adhesion molecules.
70. Fukuo K, Suhara T, Nakahashi T, Hata S, Shimizu M, Niinobu T, Morimoto S, Ogihara T. Activated T cells induce up-regulation of Fas antigen in cultured endothelial cells. Heart Vessels. 12:1997;81-83.
71. Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P, Walsh K. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci USA. 95:1998;1213-1217.
72. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. of special interest J Immunol. 158:1997;5791-5796 In this study, endothelial cells were shown to regulate passive cell death of T cells by an IL-6-dependent mechanism.
73. Strieter RM, Kunkel SL, Showell HJ, Remick DG, Phan SH, Ward PA, Marks RM. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science. 243:1989;1467-1469.
74. Topham MK, Carveth HJ, McIntyre TM, Prescott SM, Zimmerman GA. Human endothelial cells regulate polymorphonuclear leukocyte degranulation. FASEB J. 12:1998;733-746.
75. Gill EA, Imaizumi T, Carveth H, Topham MK, Tarbet EB, McIntyre TM, Prescott SM, Zimmerman GA. Bacterial lipopolysaccharide induces endothelial cells to synthesize a degranulating factor for neutrophils. FASEB J. 12:1998;673-684.
76. Lakshminarayanan V, Beno DW, Costa RH, Roebuck KA. Differential regulation of interleukin-8 and intercellular adhesion molecule-1 by H2O2 and tumor necrosis factor-alpha in endothelial and epithelial cells. J Biol Chem. 272:1997;32910-32918.
77. Goebeler M, Yoshimura T, Toksoy A, Riter U, Brocker EB, Gillitzer R. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol. 108:1997;445-451.
78. Luster AD, Unkeless JC, Ravetch JV. Gamma-inteferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 315:1985;672-676.
79. Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis I, Moser B. The chemokine receptor CXCR3 mediates rapid and shear-resitant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol. 28:1998;961-972.
80. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RA. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest. 100:1997;1047-1058.
81. Rollins BJ, Pober JS. Interleukin-4 induces the synthesis and secretion of MCP-1/JE by human endothelial cells. Am J Pathol. 138:1991;1315-1319.
82. Goebeler M, Schnarr B, Toksoy A, Kunz M, Brocker EB, Duschl A, Gillitzer R. Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology. 91:1997;450-457.
83. Douglas MS, Ali S, Rix DA, Zhang JG, Kirby JA. Endothelial production of MCP-1: modulation by heparin and consequences for mononuclear cell activation. Immunology. 92:1997;512-518.
84. Brown Z, Gerritsen ME, Carley WW, Strieter RM, Kunkel SL, Westwick J. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells. Differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon- gamma. Am J Pathol. 145:1994;913-921.
85. Polentarutti N, Introna M, Sozzani S, Mancinelli R, Mantovani G, Mantovani A. Expression of monocyte chemotactic protein-3 in human monocytes and endothelial cells. Eur Cytokine Netw. 8:1997;271-274.
86. Garcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, Hamid Q, Murphy PM, Luster AD. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol. 157:1996;5613-5626.
87. Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty BL, Springer MS, Durham SR, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol. 27:1997;3507-3516.
88. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA. 95:1998;258-263.